Navigation Links
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
Date:12/18/2007

axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with irritable bowel syndrome (IBS). Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor- selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
7. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
8. BioElectronics Corporation Announces Singapore and Malaysia Sales
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
11. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... PARK, Calif. , April 30, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... results on Thursday, May 7, 2015 after the close ... a conference call and webcast on Thursday, May 7, ... to discuss the results and recent corporate developments. ...
Breaking Biology Technology:Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3
... 2010 / PRNewswire/ -- AltheaDx, Inc. – ... of a strategic partnership with Compendia Bioscience to ... validation and bioinformatics. The two companies will jointly ... biomarker discovery and subsequent development of tests that ...
... electrical properties, carbon nanotubes are attractive building ... sensors, logic devices, and memory elements. ... arrays of individual carbon nanotubes and the ... large-scale commercial use. Now, researchers at ...
... BioSciences, Inc. (Nasdaq: SGMO ) announced today the ... correct a disease gene in an animal using systemic delivery ... four made by Sangamo,s collaborators at the 52nd Annual Meeting ... held in Orlando, Florida.   Abst.# 647 ...
Cached Biology Technology:AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panelâ„¢ 2Using new materials to make more reliable nanoelectromechanical systems 2Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting 2Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting 3Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting 4
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Scientists from the Universit de Montral and McGill University ... chemical reactions within the human body, to become highly ... a new study published in The Journal of ... an enzyme structure," says Joelle Pelletier, a professor at ...
... nearly 50 years, a population of a nearly extinct ... Forest,s San Jacinto Wilderness. Biologists from the U.S. Geological ... and scientists from the San Diego Natural History Museum ... rare mountain yellow-legged frog in the San Jacinto Wilderness ...
... University of British Columbia researchers are part of an ... land plants, a step they hope will lead to ... ultimately boost conservation efforts. Barcodes based on portions ... on products have already emerged as a viable ...
Cached Biology News:Biologists rediscover endangered frog population 2Biologists rediscover endangered frog population 3Biologists rediscover endangered frog population 4UBC researchers help push for standard DNA barcodes for plants 2
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: